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ABSTRACT 
Ovarian stimulation drugs, in particular those used in assisted reproductive technology (ART) 
treatments for infertility, have been suspected to influence cancer risk. In addition, infertility 
per se may be a risk factor for some cancer types. The focus of this thesis project was to 
examine the risk of breast and gynecological cancers among infertile women and women 
treated with ovarian stimulation. 
The four studies included in this thesis aimed to investigate: if ovarian stimulation may alter 
mammographic density (study I), if the use of ART influences the risk of breast cancer (study 
II), borderline ovarian tumors (BOT) or ovarian cancer (study III), and if infertility is 
associated with the risk of breast, ovarian or endometrial cancer (study IV). The first study 
was based on data from a screening-based cohort and the other three studies used information 
from Swedish population-based registers. 
Study I evaluated whether having a history of infertility or ovarian stimulation were 
associated with mammographic density, which is a strong risk factor for breast cancer. In 
studies II and III, cancer risk was examined among parous women who gave birth in Sweden 
between 1982 and 2012, comparing risks in women who had given birth following ART to 
that of parous women with and without infertility. In study II, breast cancer risk was also 
evaluated among women born 1960–1992, comparing the risk in women exposed to ovarian 
stimulation in 2005 or later to that of unexposed women with and without infertility. In study 
IV, the risk of breast, ovarian and endometrial cancer was assessed in women born 1942–
1992, comparing the risk in women diagnosed with infertility, ovulatory disturbances or 
endometriosis to that of women with none of these diagnoses.  
Although mammographic density was higher in women with a history of infertility, in 
particular among women exposed to ART, there was no association between infertility or 
ovarian stimulation and breast cancer risk. Ovarian cancer risk was higher among women 
diagnosed with infertility, endometriosis, and in a subpopulation of women with ovulatory 
disorders. Women who had given birth following ART treatments had a higher risk of 
ovarian cancer and BOT, which was partly explained by infertility. Endometrial cancer risk 
was higher among women diagnosed with infertility or ovulatory disturbances, but not in 
women with endometriosis.  
In conclusion, the findings suggest that infertile women have a higher risk of ovarian and 
endometrial cancer, but not breast cancer. The possible increase in ovarian tumor risk 
following ART treatments needs to be investigated further, since the results were based on a 
small number of exposed cases and may be confounded by the underlying causes of 
infertility. 
  
SVENSK SAMMANFATTNING  
Hormonella fertilitetsbehandlingar används både för att få igång normal ovulation 
(ägglossning) hos kvinnor med ovulationsrubbningar och för att få flera äggceller att mogna 
samtidigt inför assisterad befruktning. Hormonerna som används i dessa behandlingar 
påverkar i sin tur kroppens egna hormonnivåer och har misstänkts kunna öka risken för att 
utveckla cancer. Vissa orsaker till infertilitet kan också öka risken för cancer. Den 
övergripande målsättningen med denna avhandling var att undersöka risken för bröstcancer 
och gynekologisk cancer hos infertila kvinnor och kvinnor som genomgått hormonella 
fertilitetsbehandlingar.  
Studierna i avhandlingen har undersökt: om hormonella fertilitetsbehandlingar påverkar 
mammografisk brösttäthet (studie I), om assisterad befruktning påverkar risken för 
bröstcancer (studie II), cancer eller borderlinetumörer i äggstockarna (studie III) och om 
infertilitet i sig är kopplat till risken för cancer i bröst, äggstockar eller endometrium 
(livmoderslemhinna) (studie IV).  
Studie I innefattade över 43 000 kvinnor som genomgått mammografiundersökningar samt 
besvarat en omfattande livsstilsenkät i bröstcancerprojektet Karma. Övriga studier använde 
information från svenska befolknings- och hälsodataregister. I studie I undersöktes om 
infertilitet eller fertilitetsbehandlingar påverkade mammografisk brösttäthet, vilket är en stark 
riskfaktor för cancer. Sambanden mellan assisterad befruktning och cancerrisk undersöktes 
hos 1,34 miljoner kvinnor som fått sitt första barn mellan 1982 och 2012 i studie II och III. I 
studie II undersöktes också kopplingen mellan assisterad befruktning, andra hormonella 
fertilitetsbehandlingar och bröstcancerrisk bland 1,88 miljoner kvinnor födda 1960–1992. 
Slutligen undersöktes sambanden mellan infertilitet, endometrios, ovulationsrubbningar och 
cancerrisk hos 2,88 miljoner kvinnor födda 1942–1992 i studie IV.  
Resultaten från studie I visade att brösttätheten var högre hos infertila kvinnor, särskilt bland 
kvinnor som genomgått assisterad befruktning. Däremot var varken infertilitet eller assisterad 
befruktning kopplat till en högre risk för bröstcancer enligt studie II. Studie IV fann att risken 
för äggstockscancer var högre hos kvinnor med diagnoserna infertilitet, endometrios eller 
ovulationsrubbningar. Kvinnor som fött barn efter assisterad befruktning hade också högre 
risk för äggstockscancer och borderlinetumörer enligt resultaten från studie III, delvis 
beroende på den underliggande infertiliteten. Studie IV visade också på en ökad risk för 
endometriecancer hos kvinnor med infertilitet eller ovulationsrubbningar, men inte bland 
kvinnor med endometrios. 
Sammanfattningsvis verkar vissa grupper av infertila kvinnor ha en högre risk för cancer i 
äggstockar och endometrium men inte bröstcancer. Risken för bröstcancer tycks inte heller 
påverkas av fertilitetsbehandlingar. Den möjliga ökningen av äggstockstumörer efter 
assisterad befruktning behöver undersökas närmare, eftersom resultaten baserades på ett litet 
antal tumörer och risken kan ha påverkats av skillnader i den underliggande infertiliteten 
mellan kvinnor som fått barn med och utan hjälp av assisterad befruktning.   
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1 INTRODUCTION 
It has been estimated that one in seven heterosexual couples experience infertility, defined as 
trying to conceive for at least one year without success (1,2). While some eventually conceive 
spontaneously, half of these couples go on to seek medical care and about one fifth will 
receive treatment (3,4). 
Hormonal drugs that induce ovulation were developed in the middle of the 20th century and 
are still commonly used to treat infertility due to anovulation (5,6). The first successful 
treatment using assisted reproductive technology (ART) was performed in 1978 in the United 
Kingdom, followed by others in Australia, the United States, Sweden and France between 
1980 and 1982 (7). ART treatments introduced new possibilities to treat infertility caused by 
blocked fallopian tubes in women, low sperm count in men, and unexplained causes. Within 
a decade, ART became routine procedures in the fertility clinics and the number of treatments 
has increased dramatically since the middle of the 1990s. Today, around 19,000 ART cycles 
are performed each year in Sweden, contributing nearly 4% of all births (2).  
Ovulation induction and ART treatments include strong hormonal stimulation of the ovaries 
leading to increased estrogen levels which has in turn been suspected to increase the risk of 
cancer. In addition, certain causes of infertility are also risk factors for cancers (8). Although 
a number of studies have investigated cancer risk among women exposed to ovarian 
stimulation, few have been able to separate potential effects of treatment from that of 
infertility and the results are inconclusive (9,10).  
This thesis project aimed to investigate whether infertility or fertility treatments influence the 
risk of breast and gynecological cancers, using information from Swedish population-based 
registers as well as a screening-based prospective cohort.  
  
 2 
2 BACKGROUND 
2.1 REPRODUCTIVE PHYSIOLOGY 
The human menstrual cycle is regulated through an intricate system of stimulation and 
inhibition by hormones secreted in the hypothalamic-pituitary-gonadal axis (Figure 2.1). The 
hypothalamus releases pulses of gonadotropin-releasing hormone (GnRH), which regulate 
the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both from 
the anterior pituitary. In turn, these two gonadotropins regulate a cyclic function of the 
ovaries by recruitment of follicles to grow and triggering of ovulation. The hormones 
secreted by the ovarian follicles during and after these processes (estrogen and progesterone, 
respectively) induce cyclic growth and maturation of the endometrium inside the uterus (11). 
Figure 2.1 The female hypothalamic-pituitary-gonadal axis (12). Feedback to the upper levels of the axis may be 
negative or positive, i.e. inhibit or stimulate hormone secretion, respectively. 
 
The ovaries contain a population of immature primordial follicles, each consisting of an 
oocyte surrounded by a layer of granulosa cells which act as supporting cells. The ovarian 
reserve, which is constituted by the primordial follicle pool, is established during fetal life 
and steadily declines until menopause through programmed cell death (apoptosis). Starting in 
puberty, primordial follicles continuously develop into primary, secondary and tertiary (also 
called antral) follicles, independently of pituitary hormones. At the tertiary or antral stage, the 
follicles acquire receptors for FSH and can respond to pituitary hormones.  
In the early follicular phase of the menstrual cycle (Figure 2.2), the secretion of FSH by the 
pituitary gland stimulates the growth and development of a group of antral follicles in the 
ovaries. Eventually, one of the recruited follicles will become selected and dominant while 
the remaining undergo regression and will die. Follicle selection and dominance are mainly 
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Figure 2.2 The menstrual cycle (13). 
 
regulated by the high estrogen secretion from the granulosa cells of the dominant follicle, 
which induces a negative feedback loop causing the FSH levels to decrease. Hence, the 
stimulation of additional follicles in inhibited. When the dominant follicle reaches a large and 
critical size, its sustained and high estrogen secretion also leads to a surge in LH inducing 
final maturation and ovulation. During follicle growth and dominance, a rapid proliferation of 
the endometrium occurs in response to the estrogen secretion.  
The luteal phase is initiated after ovulation, in the middle of the cycle (around day 14 of 28). 
In the early luteal phase, the granulosa cells of the ruptured follicle transform into a structure 
called the corpus luteum which produces progesterone and estrogen, causing further 
proliferation and thickening of the endometrium to make it receptive for implantation. The 
mature oocyte enters the fallopian tube where fertilization can take place in the presence of 
spermatozoa. Pregnancy occurs if a resulting embryo is successfully implanted into the 
receptive endometrium. After implantation, the developing placenta produces human 
chorionic gonadotropin (hCG) which stimulates continued progesterone production from the 
corpus luteum and sustains the endometrium. If implantation does not occur, the corpus 
luteum regresses completely approximately two weeks after ovulation. The resulting drop in 
progesterone and estrogen causes the menstrual bleeding and releases the hypothalamus from 
the negative feedback, which in turn causes FSH secretion to increase and a new menstrual 
cycle to begin. 
 4 
2.2 FEMALE INFERTILITY  
The World Health Organization (WHO) has defined infertility as “a disease of the 
reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or 
more of regular unprotected sexual intercourse” (14). This means that it is still possible for an 
infertile couple to conceive spontaneously, in contrast to sterility. In this thesis, the term 
infertility generally refers to the WHO definition, which is commonly used clinically and in 
epidemiological research. There are several other definitions used depending on research 
field, study question and data available (1).  
Among heterosexual couples who seek medical treatment for infertility, female factor 
infertility alone accounts for 20-35% of cases, male factor infertility explains 20-30% of 
cases and 25-40% of cases involve both partners. In 10-25% of cases, no cause can be 
identified and this is defined as unexplained infertility (2,7,15,16).  
Fertility is strongly linked to the woman’s age, mainly due to the natural depletion of the 
ovarian reserve and decreased oocyte quality with aging. This age-related decline in female 
fertility has been shown to accelerate after the age of 37, and spontaneous pregnancies in 
women over 45 years of age are very rare (6,17). In women of reproductive age, the main 
causes of infertility are ovulatory dysfunction, structural abnormalities and endometriosis 
(7,18).  
Ovulatory dysfunction includes both anovulation and oligoovulation, i.e. missing or 
infrequent ovulation. The most common cause of ovulatory dysfunction is polycystic ovary 
syndrome (PCOS), an endocrine disorder characterized by high androgen levels, polycystic 
ovaries and menstrual disturbances due to oligo- or anovulation. PCOS is often associated 
with insulin resistance and obesity, which can negatively affect oocyte maturation, 
fertilization and implantation. Ovulatory dysfunction can also be caused by premature 
ovarian insufficiency and disorders of the hypothalamus or pituitary (19). 
Structural causes of infertility encompass tubal and uterine factors, with tubal factors being 
the most common. Tubal damage is most often caused by pelvic inflammatory disease 
following infections. Pelvic surgery and severe endometriosis can also damage the fallopian 
tubes. Uterine causes of infertility include congenital malformations of the uterus and 
acquired conditions such as benign uterine tumors (20).  
Endometriosis is an inflammatory disease characterized by endometrial tissue growing 
outside the uterine cavity, commonly associated with chronic pelvic pain and infertility. 
Previous studies have estimated that endometriosis affects 5-15% of all women of 
reproductive age, and 25-40% of infertile women. Endometriosis has been suggested to 
interfere with fertility through pelvic adhesions, ovulatory dysfunction, impaired fertilization 
and implantation, embryo toxicity, and sperm phagocytosis, although the exact mechanisms 
are not yet known (20,21). 
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2.3 FERTILITY TREATMENTS 
The main aim of hormonal fertility treatments is to stimulate ovulation or superovulation by 
acting on the hypothalamic-pituitary-gonadal axis. Ovulation induction refers to treatments 
that increase the chances of spontaneous conception by restoring normal ovulatory cycles, 
while ART refers to fertility treatments where both oocytes and sperm are handled in vitro 
(22). In this thesis, ovarian stimulation refers to both ovulation induction and ART. 
Fertility treatments are provided within the Swedish tax-funded healthcare system and 
treatments are individualized based on the identified causes of infertility (6). The established 
clinical practice (Figure 2.3) includes ovulation induction using clomiphene citrate as the 
first-line treatment for anovulatory infertility if no additional infertility factors are present. If 
unsuccessful, low-dose gonadotropin stimulation may be used to obtain ovulation and 
subsequently ART is used as a final line treatment. The first choice for mild male factor or 
unexplained infertility is intrauterine insemination with or without ovulation induction. For 
infertility due to endometriosis, severe male factor or tubal factor, ART is recommended as 
the first-line treatment. Since age has a large impact on female fertility, women older than 36 
years of age or who present with a strongly reduced ovarian reserve are preferably treated 
directly with ART to increase the chances of success. Surgical treatment is occasionally 
required for severe endometriosis, malformations and certain tubal or uterine factors (6).  
 
2.3.1 Ovulation induction 
Ovulation induction treatments encompass hormonal medications used to restore the natural 
ovulatory cycle in women with irregular cycles and anovulation. Experimental treatments to 
induce ovulation in humans were performed as early as the 1930s, using gonadotropins from 
pig, sheep and mare. Though a number of pregnancies were reported, these preparations also 
triggered the formation of antibodies and the treatments were eventually stopped due to safety 
concerns. The first reports of pregnancies following human gonadotropin stimulation were 
published in 1962. The early gonadotropin preparations contained both FSH and LH which 
Figure 2.3 Treatment algorithm for infertility (CC clomiphene citrate, Gn gonadotropins). 
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limited their efficiency, and methods to purify FSH from human menopausal gonadotropin 
were developed over the next decades. Preparations of pure FSH produced using recombinant 
gene technology became available in the early 1990s (23).  
Clomiphene citrate belongs to a group of anti-estrogens first synthesized in the late 1950s. 
When these drugs were tested in patients with endometrial hyperplasia, they were found to 
restore menstruation in women with PCOS (5). Following this surprising discovery, 
clomiphene citrate was approved for the treatment of anovulatory infertility in 1962 in the 
United States and is still the most commonly used fertility drug worldwide. Clomiphene 
citrate is known to inhibit the negative feedback of estrogen on the hypothalamus which leads 
to increased secretion of FSH from the pituitary gland (5).  
In Sweden, both clomiphene citrate and gonadotropins have been used for ovulation 
induction since the 1960s (24). Ovulation induction is usually followed by an injection of 
hCG, called a trigger shot, which mimics the natural LH surge to trigger the final maturation 
of the oocyte and ovulation (6).  
2.3.2 Assisted reproductive technology (ART) 
ART treatments generally encompass a step-by-step procedure including controlled ovarian 
stimulation (COS) for the retrieval of oocytes by transvaginal and ultrasound-guided ovarian 
puncture, the fertilization of oocytes with sperm in a laboratory to produce embryos which 
are subsequently cultured during a few days before being transferred into the woman’s uterus. 
In COS, high and sustained doses of gonadotropins are injected to eliminate the selection 
mechanism and support the growth of multiple follicles during a single cycle. 
The first live birth following ART treatment was reported in 1978 (25). This groundbreaking 
achievement was accomplished within a natural cycle, where laparoscopic extraction of the 
single mature oocyte had to be carefully timed with the woman’s ovulation. Reports of other 
successful ART soon followed. The procedures were further developed and a few years later, 
COS using either clomiphene citrate or gonadotropins replaced natural-cycle ART. In around 
20% of the early treatments with COS, the high levels of estrogen induced an early LH surge, 
causing ovulation before the mature oocytes could be extracted. In order to avoid this, 
suppression of GnRH was introduced to the treatment protocol in the 1980s (25).  
The modern ART procedure follows several steps. Gonadotropins for COS are normally 
administered in the early follicular phase of the ovulatory cycle. COS has been performed 
with gonadotropins alone in Sweden since the mid-1990s, before which both clomiphene 
citrate and gonadotropins were used (26). The most commonly used gonadotropin for ART in 
Sweden is recombinant FSH. 
Prevention of spontaneous ovulation can be achieved by either GnRH agonists or antagonists, 
depending on the protocol used. In the long protocol, administration of a GnRH agonist is 
often initiated in the luteal phase of the cycle previous to the treatment. GnRH agonists 
stimulate the pituitary initially triggering an increase of FSH and LH, called a flare. 
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Continued GnRH agonist administration leads to downregulation of the gonadotropin 
receptors on the pituitary and decreased levels of FSH and LH. GnRH antagonists have also 
been developed. They have a similar effect, suppressing GnRH action on the pituitary 
immediately and completely, causing decreased FSH and LH levels without the initial flare. 
In the short protocol, administration of GnRH antagonists is initiated a few days after COS 
has been started.  
After 10-12 days of stimulation, a single injection of hCG is given to trigger the final stage of 
oocyte maturation. The mature oocytes are collected from the follicles using an ultrasound-
guided needle just before they would have been released into the fallopian tubes. In standard 
in vitro fertilization (IVF) sperm are added to the oocytes in a Petri dish. A single sperm can 
also be injected directly into the center of the oocyte in a procedure called intracytoplasmic 
sperm injection (ICSI). Normally, one or two of the resulting embryos are transferred to the 
uterus using a soft catheter, while additional embryos can be frozen for later attempts. Since 
the ART procedures lower endogenous LH levels, luteal support with progesterone is needed 
to support implantation and early embryogenesis (6).  
Figure 2.4 Total number of births and multiple births following ART in Sweden 1982–2012. Based on data 
from the National Board of Health and Welfare and the Q-IVF registry. 
 
During the 1980s, the total number of ART births in Sweden were less than 400 (Figure 2.4). 
Since the 1990s, the number of treatments has increased dramatically. In 2012, there were 
more than 3,500 deliveries following ART, accounting for 3.8% of all births in Sweden in 
2012 (27). The multiple birth rate following ART has historically been very high. In Sweden, 
a gradual shift to double and single embryo transfers successfully decreased the multiple birth 
rate from 32% in 1991 to under 5% in recent years (28,29). Oocyte donation was legalized in 
Sweden in 2003, and accounted for less than 100 (3%) of the ART births in 2012 (29). 
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2.4 CANCER, INFERTILITY AND FERTILITY TREATMENTS  
Cancers are broadly classified according to their anatomical location and by the tissue or cell 
type where they originated. Different cell types give rise to cancers that differ in appearance, 
behavior and prognosis. Etiology and risk factors for different cancers also vary considerably. 
Carcinomas, cancers of epithelial origin, account for 90% of all cancer cases (30). The 
characteristics and risk factors described in this chapter are based on studies where the 
majority of cancers were carcinomas, and do not necessarily apply to cancers that arise from 
other cell types such as connective tissue or germ cells.  
This thesis project has focused on cancers of the breast, ovary and endometrium. These 
cancer types are commonly associated with hormonal and reproductive factors and could 
therefore potentially be influenced by infertility or fertility treatments (31–33).  
There are several challenges when investigating cancer risk following fertility treatments. 
The underlying causes of infertility, reproductive factors such as not having children or 
giving birth at a later age, and ovarian stimulation treatments often occur together making it 
difficult to disentangle the potential effect of treatment from that of infertility per se. Cancer 
is also a relatively rare outcome, which is usually diagnosed decades after the reproductive 
period, while most women who have received ovarian stimulation so far are still young.  
Increasing age is the most important risk factor for the cancers covered in this thesis. Figure 
2.5 shows the crude incidence rates of these cancers in Sweden by age group. Breast cancer 
incidence starts increasing before age 30, while ovarian and endometrial cancer are generally 
diagnosed in older women. Over the last decades, the incidence of breast cancer has increased 
while both ovarian and endometrial cancers have become less common (30).  
Figure 2.5 Incidence rates of breast, ovarian and endometrial cancer in Sweden 1982–2012, by age (34). 
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2.4.1 Breast cancer 
Breast cancer is the most common cancer type in women, representing 27% of all cancer 
cases among women in Sweden (35). Not having children, early menarche, late menopause, 
higher age at first birth and not breastfeeding are established risk factors for breast cancer 
(36,37). A temporary increase in breast cancer risk has been shown for current or recent use 
of oral contraceptives at reproductive age or hormone replacement therapy in postmenopausal 
years (31). Some studies have also suggested associations between breast cancer risk and 
infertility (38–40), endometriosis (41,42), and PCOS (43,44). 
Both clomiphene citrate and gonadotropins have been suspected to influence the risk of breast 
cancer through increased serum concentrations of endogenous estrogen (9). Reassuringly, 
most previous studies and meta-analyses have not shown an increased risk of breast cancer 
following ovarian stimulation (38,45–52). Another recent meta-analysis found no association 
between ART and breast cancer, but indicated a small increase in risk following non-ART 
treatments of infertility (9). Additionally, a large cohort study from Norway reported that 
women who gave birth following ART had a small but statistically significant increase in 
breast cancer risk compared to other parous women (53). Some studies have also shown an 
increased risk of breast cancer in subpopulations of infertile women, including women who 
remained nulliparous following gonadotropin stimulation (54,55), commenced their ART 
treatment at a young age (56), started treatment after age 30 (57), underwent four or more 
cycles of ART (58), and women treated with high-dose clomiphene citrate therapy (24). 
Mammographic density 
Mammographic density, referring to the amount of radiologically dense fibroglandular tissue 
in the breast, is a strong marker of breast cancer risk (59,60). Mammographic density is 
associated with both the risk of developing breast cancer and the risk of not detecting a cancer 
in the screening program (61). High density is also related to reproductive characteristics, 
such as low parity and high age at first birth (62). These features suggest that mammographic 
density is an intermediate phenotype in breast cancer etiology (63), making it an interesting 
trait to study in relation to ART since most women who have gone through treatment are 
currently still below the age when breast cancer is usually diagnosed.  
Few studies have evaluated breast mammographic features in selected populations of infertile 
women. A study by Sprague et al. (2008) found that women more recently dispensed a 
fertility drug had lower density, although there were no associations between fertility drug 
use and mammographic density overall (64). In two more recent studies, Meggiorini et al. 
reported higher breast density in women with ovulatory infertility compared to women with 
other infertility types (65), and in women with primary infertility compared to parous women 
(66). 
 10 
2.4.2 Ovarian cancer 
Ovarian cancer accounts for 3% of incident cancers but over 5% of cancer-specific mortality 
among women in Sweden (35). Since early symptoms are few and unspecific, ovarian cancer 
is often diagnosed at an advanced stage when it is more difficult to treat and cure. The risk of 
ovarian cancer is higher among women with early menarche, late menopause, nulliparity and 
endometriosis (67,68). In contrast, oral contraceptive use and high age at first as well as last 
birth are associated with a lower risk of ovarian cancer (69,70). Around 10-15% of ovarian 
cancer cases are hereditary (71). Some studies have also found an increased risk of ovarian 
cancer among women with irregular menstruation (72) and women evaluated for infertility 
(39,40,73). 
Two different theories have been proposed to explain these associations: the incessant 
ovulation theory and the elevated gonadotropins theory. The first hypothesizes that the 
damage and repair of the ovarian epithelium during ovulation leads to an increased ovarian 
cancer risk, while the latter suggests that stimulation of the ovarian epithelium by endogenous 
gonadotropins causes the risk increase. As ovarian stimulation increases the levels of 
circulating gonadotropins and stimulates ovulation, both of these theories propose a link 
between treatment and ovarian cancer risk (74).  
Numerous studies have investigated the associations between ovarian stimulation and ovarian 
cancer risk. Most studies to date have not found an increased risk of ovarian cancer following 
either ART (46–48,68,75,76) or ovulation induction (38,45,77–80). However, some studies 
have reported higher risks of ovarian cancer following ART (26,81) and ovulation induction 
(50,82,83). Only two of these studies included comparisons to untreated infertile women, 
where one reported a higher risk among women treated with clomiphene citrate who 
remained nulliparous (82), and the other a higher risk following stimulation with 
gonadotropins alone (83). Consequently, it remains unclear whether any ovarian stimulation 
treatments may influence ovarian cancer risk or if the associations were due to the underlying 
infertility. 
Borderline ovarian tumors 
Borderline ovarian tumors (BOT) are intermediate between benign and invasive ovarian 
tumors, accounting for around 15% of primary epithelial ovarian tumors in Sweden. These 
tumors are more common in younger women and have a better prognosis than ovarian cancer. 
In Sweden, the incidence of BOT has increased while ovarian cancer incidence has declined 
since the 1980s (84). Although they are generally considered to be separate diseases, BOT 
and ovarian cancer share similar risk factors (85,86). The results of some previous studies 
have also suggested that infertility (86), ART (50,76,87) and ovulation induction (83) may 
increase the risk of BOT.  
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2.4.3 Endometrial cancer 
Endometrial cancer, originating from the inner lining of the uterus, is the most common 
gynecological malignancy. In Sweden, endometrial cancer accounts for 5% of incident cases 
among women (35). Lifestyle factors such as obesity, diabetes mellitus and hypertension are 
known risk factors for endometrial cancer. Nulliparity, late menopause and PCOS also 
increase the risk, while oral contraceptive use, physical activity, cigarette smoking, increased 
parity, and giving birth late in life seem to be protective. Hormone replacement therapy using 
only estrogen has also been shown to increase the risk of endometrial cancer, while 
combination therapy with estrogen and gestagens do not (33,88). Many of the identified risk 
factors are associated with increased levels of estrogen without opposing progesterone, a 
situation that has been consistently found to elevate endometrial cancer risk (88). 
Several studies have reported a higher risk of endometrial cancer among infertile women 
(38,40,45,89). The associations may be due to PCOS, although these studies did not have 
information on the causes of infertility. Some studies have also suggested that endometriosis 
could increase the risk of endometrial cancer (41,90), while others have not (42,91,92). 
A recent systematic review found a higher risk of endometrial cancer following ovarian 
stimulation, in particular for multiple cycles of clomiphene citrate, although the authors noted 
that the association could still be due to the underlying infertility (93).  
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3 AIMS 
The overarching aim of the thesis project was to perform a large population-based assessment 
of whether infertility or the use of assisted reproductive technology impacts cancer risk. 
The specific research questions for each study in this thesis were: 
 Study I: Does ovarian stimulation alter mammographic density? 
 Study II: Does ovarian stimulation affect the risk of breast cancer? 
 Study III: Do ART treatments influence the risk of invasive ovarian cancer or 
borderline ovarian tumors in parous women? 
 Study IV: Is infertility associated with the risk of breast, ovarian or endometrial 
cancer and, if so, can ovulatory disturbances or endometriosis explain the association? 
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4 MATERIALS AND METHODS 
4.1 DATA SOURCES  
Information from Swedish national population-based registers and quality registers was used 
in all four studies. The unique personal identification numbers assigned to all Swedish 
residents enables individual record linkage (linking) of these registers. Studies II-IV were 
based entirely on data from the national registers while study I also used data from a 
prospective breast cancer cohort called Karma.  
4.1.1 The Multi-Generation Register (MGR)  
The Swedish Multi-Generation Register (MGR), held at Statistics Sweden (Statistiska 
Centralbyrån), is a register of individuals born 1932 or later and residing in Sweden at any 
time since 1961 (94). The MGR links these so-called index persons to their biological and 
adoptive parents. Statistics Sweden created the MGR in the year 2000 using information from 
the population registry held by the Swedish Tax Agency and updates it yearly. Parents of 
index persons must have resided in Sweden in 1947 or later to be included in the MGR. 
Information on parents is also missing for around 40% of the index persons who died before 
July 1991, when the church was responsible for administration of the population registry. 
4.1.2 The Medical Birth Register (MBR)  
The Medical Birth Register (MBR) was started in 1973 by the National Board of Health and 
Welfare (NBHW, Socialstyrelsen). The MBR contains detailed information on all childbirths 
in Sweden, obtained from medical records of prenatal, delivery and neonatal care (28). For 
the purpose of monitoring children born through ART treatments, information on ART 
treatments leading to a live birth was retrospectively collected from IVF clinics by the 
NBHW for the years 1982–2006 and linked to the MBR (28,95). This information includes 
the date of embryo transfer, ART method used and the personal identification number of 
mothers and children.  
4.1.3 The National Quality Registry for Assisted Reproductive Technology 
(Q-IVF)  
The National Quality Registry for Assisted Reproductive Technology (Q-IVF) covers ART-
treatments performed in Sweden since 2007. All ART cycles are recorded in the registry, 
including those that do not lead to pregnancy or live birth. The registry is administered jointly 
by all ART clinics in Sweden and contains detailed information about each cycle of ART, 
including stimulation protocol, oocytes and sperm used, fertilization method, number of 
embryos transferred, treatment results and the date of each treatment step. The personal 
identification number for both parents is also recorded.  
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4.1.4 The National Patient Register (NPR)  
The National Patient Register (NPR), held at the NBHW, was established in 1964. During the 
first year, somatic in-patient care was collected from six Swedish counties as a pilot project. 
Gradually, more counties joined the project and the NPR covered 85% of all hospital 
discharges in 1983. Since 1987, the NPR has complete national coverage of in-patient care. 
Registration of surgical procedures in out-patient care was introduced in 1997 and expanded 
in 2001 to include all specialist out-patient care, with an estimated completeness of around 
80% (96,97). 
The records in the NPR include the personal identification number of the patient, date of 
admission and discharge, primary diagnosis, up to eight additional diagnoses and any surgical 
procedures performed during the visit. Each diagnosis is coded using the current version of 
the International Classification of Disease (ICD). ICD version 7 was used until 1968, ICD-8 
1969–1986, ICD-9 1987–1996, and ICD-10 from 1997. Skåne County switched to ICD-10 in 
1998. Surgical procedures were coded using a national classification system in 1964–1996 
(98) and changed to a Nordic system in 1997 (99). Consequently, both the codes for 
diagnoses and surgical procedures have changed during the period covered in the included 
studies.  
4.1.5 The Prescribed Drug Register (PDR)  
The Prescribed Drug Register (PDR), held at the NBHW, includes every dispensation of 
prescription drugs at Swedish pharmacies since July 2005. The PDR is automatically updated 
every month (100). In addition to the personal identification number of the patient, each entry 
in the register contains information on date of prescription and dispensation, the brand name 
of the prescribed drug and its active substance coded using the Anatomical Therapeutical 
Chemical (ATC) classification system from the WHO. The PDR does not contain 
information on vaccines or drugs administered in hospital in-patient care.  
4.1.6 The Swedish Cancer Register (SCR)  
The Swedish Cancer Register (SCR) records all occurrences of primary malignant tumors, as 
well as certain primary non-malignant tumors, in Swedish residents since 1958. Each entry 
includes date of diagnosis, tumor site, clinical and morphological diagnosis, as well as 
information about the patient and the reporting hospital. The tumor location is coded using 
the current version of the International Classification of Diseases for Oncology (ICD-O), and 
tumor morphology according to ICD-O and the Systematized Nomenclature of Medicine 
(Snomed). Table 4.1 describes when new coding systems and versions were added to the 
SCR (101). Both location and morphology codes are translated to previously used coding 
systems, so that all tumors registered in the SCR since 1958 have an ICD-7 location code and 
morphology coded using a historical three-digit system (C24) developed by the WHO in 
1956 (102). The SCR has an estimated completeness of over 96% for gynecological cancers 
and 98% for breast cancers (103).  
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Table 4.1 Coding systems used for tumors in the SCR. 
Year Location Morphology 
1958 ICD-7 C24 
1987 ICD-9  
1993 ICD-O/2 Snomed (ICD-O/2) 
2005 ICD-O/3 Snomed (ICD-O/3) 
4.1.7 Other registers 
The Education Register includes the current highest educational level, place of education and 
personal identification number for Swedish residents. Statistics Sweden administers the 
register which contains information reported from all schools and universities since 1985.  
Migrations in and out of Sweden are recorded in the Total Population Register, held at 
Statistics Sweden. Emigrations out of Sweden have been included since 1961, and 
immigrations since 1969. The available data includes the date and direction of each migration 
as well as the personal identification numbers.  
Information on date and cause of death for Swedish residents is recorded in the Cause of 
Death Register since 1961. There is also a historical register covering the years 1952–1960, 
and both of these registers are held at the NBHW. 
4.1.8 The Karma cohort  
Study I was based on data from the Karolinska Mammography Project for Risk Prediction of 
Breast Cancer, Karma, which is a screening-based breast cancer cohort (104). Between 2010 
and 2013, more than 70,000 women were recruited to Karma from four participating 
mammography units in Stockholm County and Skåne County. In Sweden, all women aged 40 
to 74 years are invited to mammography screening at an interval of 18 to 24 months. The age 
groups which are offered screening have varied over time, and ages 70 to 74 were not 
included in the Stockholm screening program until 2013 (105). Detailed information on the 
women’s background and reproductive health, including menstruation history, fertility 
problems and treatments, medication, alcohol and tobacco use, chronic diseases, life-style 
factors and family history of cancer was collected in a comprehensive self-report 
questionnaire at the first screening visit. Digital mammographic images are stored after each 
screening visit. Information from national registers, including the NPR, SCR, PDR and the 
Cause of Death Register, is linked to the cohort and updated every six months.  
4.1.9 Register linkage for studies II-IV 
Studies II-IV were based on data from Statistics Sweden, the NBHW and the Q-IVF registry. 
The index population consisted of all women born between 1932 and 2012 and registered as 
index persons in the MGR at any time from 1961 until 2012. Statistics Sweden identified the 
population and created a key file linking the personal identification numbers to randomly 
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assigned sequence numbers. The personal identification number was replaced with these 
sequence numbers in all data delivered for research. 
Information on ART has been retrieved from the NBHW (1982–2006), from the PDR (July 
2005–2012) and from the Q-IVF registry for the years 2007–2012. For the years 1982–2006 
only information on ART treatments leading to a live birth was available, while the Q-IVF 
registry contains information on all ART cycles (including unsuccessful treatments). The 
PDR was used to find information on dispensations of ovulation-stimulating drugs since 2005 
and onwards. Medical information including diagnoses of infertility and cancer was also 
obtained from the registers held at the NBHW. Socioeconomic data such as education, 
country of birth and migrations was provided by Statistics Sweden.  
4.1.10 Ethical considerations  
Research conducted in Sweden that involves individual human beings is regulated by the 
Ethical Review Act (2003:460), The Public Access and Secrecy Act (2009:400) and the 
Personal Data Act (1998:204). The regulations protect study participants against the risk of 
physical injury, mental injury or the violation of integrity. Research that includes the handling 
of sensitive personal data may only be conducted following an ethical vetting process which 
provides an approval. The ethical vetting process includes weighing the risks or harms 
involved against the potential gain of knowledge by the proposed research. 
Study I used data from the Karma cohort. Ethical permission for the Karma project was 
obtained in 2010 (2010/958-31/1). The ethical approval was updated in 2014 in order to link 
ART information to the cohort (2014/11-32). More than 70,000 women attending 
mammography screening between 2010 and 2013 were recruited to Karma. All women who 
chose to participate in the study provided written informed consent. They were also informed 
that they can withdraw from the study at any time (page 19-24 in the ethical application 
form). In the datasets used for the studies in this thesis, personal identification numbers were 
replaced by unique study participant numbers and other personal identifiers were removed 
before the research team gained access to the data.  
Ethical approval for the register linkage used in studies II-IV was granted in 2013 
(2013/1849-31/2) and updated in 2014 (2014/118-32). All of the information used in these 
studies was obtained from registers at central authorities and national quality registers in 
Sweden and the project, including eleven million individuals, was granted an exception to the 
requirement of informed consent. The personal identification numbers have been replaced by 
randomly generated unique sequence numbers and the key is held at the NBHW for future 
updates. The research team did not have access to the original identification numbers but only 
the random sequence numbers. 
All of the four studies involved handling of large amounts of sensitive personal information. 
While the files do not contain any names, addresses or personal identification numbers, it 
would still be possible to identify specific individuals through other information such as their 
date of birth and medical history. However, as researchers we are obliged by law to protect 
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the privacy of the participants and not misuse any information discovered. The data is 
handled and stored in a secure way to minimize the risk of data misuse, and the results are 
presented in an aggregated form so that identification of individual participants is not 
possible. 
These and other similar studies contribute important knowledge about the effects of infertility 
and fertility treatments on human health. The results may be used to improve diagnosis and 
treatment of infertility and might also identify risk factors for cancer development. 
4.2 MEASUREMENTS, ASCERTAINMENT AND DATA QUALITY 
4.2.1 Infertility  
In study I, women with a history of infertility were identified using self-reports. The Karma 
questionnaire included the question “Have you ever tried to become pregnant for one year or 
more without success?” corresponding to the WHO definition of infertility.  
Table 4.2 Infertility-related diagnoses in the NPR. 
Diagnosis 
ICD-7 
1964–68 
ICD-8 
1969–86 
ICD-9 
1987–96 
ICD-10 
1997– 
Female infertility 636 628 628 N97 
   Due to anovulation n/a n/a 628A N97.0 
   Due to endometriosis n/a n/a n/a N97.8D 
Endometriosis n/a  625,3 617 N80 
Ovarian dysfunction 275 256 256 E28 
Absent, scanty or rare menstruation 634,10-634,12 626,00-626,11 626A-626B N91.1-N91.5 
n/a indicates that the diagnosis was not available in the current version of ICD. 
The diagnosis codes listed in Table 4.2 were used to define a comparison group of women 
with fertility-related problems in study II. A stricter definition, including only women 
diagnosed with infertility, was used to identify a comparison group in study III. In study IV, 
the diagnoses in Table 4.2 were used to subdivide women with and without infertility 
diagnosis into three groups having ovulatory disturbances, endometriosis, or neither. 
Infertility was defined as any diagnosis of female infertility, ovulatory disturbances as any 
diagnosis of ovarian dysfunction, menstrual disturbances, or infertility due to anovulation, 
and endometriosis as any diagnosis of endometriosis or infertility due to endometriosis. The 
definitions used in each study are summarized in Table 4.3. 
Table 4.3 Definitions of infertility and related diagnoses used in study II-IV.  
Infertility-related 
diagnosis 
Study II 
Infertility  
 
Studies III and IV 
Ovulatory 
disturbances  
Study IV 
Endometriosis  
 
Study IV 
 Female infertility of 
any cause 
 Endometriosis 
 Ovarian dysfunction 
 Absent, scanty or rare 
menstruation 
 Female infertility of 
any cause 
 Ovarian dysfunction 
 Absent, scanty or rare 
menstruation  
 Female infertility due 
to anovulation 
 Endometriosis 
 Female infertility due 
to endometriosis 
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4.2.2 Ovulation induction and controlled ovarian stimulation 
In the Karma questionnaire, women reporting a history of infertility were also asked if they 
had ever received fertility treatment and if so, which of the following: hormonal treatment 
only, sperm insemination, IVF/ICSI, IVF with egg donation, surgical treatment, and other 
treatment. Women answering ‘other treatment’ were asked to describe the treatment in an 
open field. In study I, the answers were used to define three treatment categories: COS, 
ovulation induction, and no hormonal treatment. The COS category consisted of women who 
had ever been treated with COS for ART (IVF or ICSI). IVF with egg donation was 
categorized as non-hormonal since women receiving donated eggs do not require COS. 
Women who had answered ‘hormonal treatment only’, or described using either clomiphene 
citrate (Pergotime, Clomivid) or cyclofenil (Sexovid) in the open field were included in the 
ovulation induction category. The majority of women in the category ‘no hormonal 
treatment’ had not received any fertility treatment, while a small fraction had gone through 
non-hormonal treatments including surgery and insemination.  
In study II, the PDR was used to identify women who had gone through ovulation induction 
or COS for ART. COS was defined as dispensations of gonadotropins and GnRH analogues 
(either agonist or antagonist). In the short COS protocol, GnRH antagonist treatment is 
normally initiated a few days into the stimulation and prescribed at the same time, while 
down-regulation with GnRH agonists is initiated 10-14 days prior to stimulation in the long 
protocol. Up to 90 days was allowed between dispensations of down-regulation and 
stimulation, in case the GnRH analogue had been dispensed for a previous treatment cycle. 
Ovulation induction was defined as dispensations of either clomiphene citrate or 
gonadotropins without down-regulation. Trigger shots with hCG were not included in the 
algorithms since they are used in both COS and ovulation induction. The names and ATC-
codes of included fertility drugs are listed in Table 4.4. 
Table 4.4 Prescribed drugs used to treat infertility with corresponding ATC-codes.  
Ovarian stimulation Down-regulation 
clomiphene citrate, G03GB02 GnRH agonists 
Gonadotropins nafarelin, H01CA02 
menotropin, G03GA02 buserelin, L02AE01 
urofollitropin, G03GA04 triptorelin, L02AE04 
follitropin alfa, G03GA05 GnRH antagonists 
follitropin beta, G03GA06 ganirelix, H01CC01 
chorifollitropin alfa, G03GA09 cetrorelix, H01CC02 
4.2.3 ART births  
In studies II and III, information from the NBHW and the Q-IVF registry were used to 
identify women with ART births 1982–2012. ART births between 1982 and 2006 were 
identified by linking the NBHW information to the MGR, using the unique sequence 
numbers of each mother and child. For the later years, information on embryo transfer date 
and delivery date in the Q-IVF registry was used. Since the Q-IVF registry does not record 
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the personal identification number of the children, it was linked to the MGR using the 
sequence number of the mother and the birthdate of the child. When the birthdate of the child 
did not match, a birth in the MGR within ten months of an embryo transfer in the Q-IVF 
registry was categorized as an ART birth. Both fresh and frozen cycles from standard IVF 
and ICSI were included. Additionally, ART using donated oocytes were included since 
information on oocyte origin was missing for the years 2003–2006.  
4.2.4 Mammographic density 
In study I, associations between infertility, fertility treatments and mammographic density 
were examined. Volumetric measures of density were obtained from digital mammograms 
using a fully automated method (106). The method computes the volume of dense 
fibroglandular tissue and the total breast volume. Percent dense volume is the ratio between 
the absolute dense volume and the total breast volume. The absolute non-dense volume, or 
amount of fatty tissue, was calculated as the difference between the total and dense volume. 
Both absolute and relative dense volume have been shown to be associated with breast cancer 
risk (61,107). For completeness, analyses of all three measures were included in the study. 
4.2.5 Cancer  
Incident cancers were identified using information from the SCR. The first occurrence of 
cancer for each woman was included in the studies II, III and IV, and the date of diagnosis 
was used to identify cases or for censoring follow-up time. 
In study II, breast cancer was defined as adenocarcinoma of the breast using ICD-7 code 170 
and C24 code 096. This definition was used to identify cancer cases as well as history of 
breast cancer in first-degree family members (biological mothers and sisters). 
In study III, ovarian cancer was defined as any malignant tumor of the ovary, fallopian tubes, 
broad ligaments (ICD-7 175) or peritoneum (ICD-7 158). Tumors at these sites have similar 
characteristics and treatment (71). Epithelial tumors were identified using the C24 code 096. 
Borderline malignant ovarian tumors were defined as tumors with ICD-7 code 175 and 
C24 code 094. Separate analyses were performed for BOT and ovarian cancer, and women 
diagnosed first with BOT and later with ovarian cancer were included as cases in both 
analyses. 
In study IV, cancers of the breast, ovary (including fallopian tubes and broad ligaments) and 
endometrium (ICD-7 170, 175 and 172, respectively) were included. Separate analyses were 
performed for each cancer type, and women diagnosed with multiple primary malignant 
tumors at the same date were included as cases for each cancer type.  
Women diagnosed with any malignant tumor (ICD-7 140-105) before each study were 
excluded. In analysis of BOT incidence, women diagnosed with BOT before the study were 
also excluded. 
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4.2.6 Other covariates 
In study I, the multivariable adjusted model included age at mammography, body mass index 
(BMI, calculated from height and weight as kg/m2), cigarette smoking, alcohol consumption, 
education level, family history of breast cancer, age at menarche, menopausal status, and 
parity. Breast cancer in first-degree relatives (mothers, sisters and daughters) was identified 
using the SCR, while the other covariates were retrieved or calculated from questionnaire 
data. 
All multivariable analyses in studies II-IV were adjusted for age, parity, calendar time, 
education level and age at first birth. In study II, family history of breast cancer was also 
included, while family history of either breast or ovarian cancer was included in study III. 
Bilateral oophorectomy, hysterectomy and salpingectomy were included as covariates or used 
for censoring depending on the cancer type in studies III and IV. 
4.3 STUDY DESIGNS 
This thesis includes four observational studies. Study I was a cross-sectional study based on a 
screening cohort where all of the information was collected at a specific time. The other three 
studies were population-based cohort studies where information on exposure, outcome and 
other covariates had been continuously recorded in national registers over the course of the 
study follow-up. 
Study population in study I  
All women aged 40 to 69 years with digital mammograms from the first mammography visit 
were selected from the Karma cohort. Women with cancer or breast surgery before 
mammography, and women with incomplete covariate information were excluded. 
Cohort of parous women in studies II and III 
Since only information on ART treatments leading to live births was available for most of the 
time that ART has been used in Sweden, the study population was restricted to women with 
live births 1982–2012. Initially, all women who had their first child during this calendar 
period were identified using information from the MGR. The women were followed from the 
start of pregnancy resulting in their first child. Pregnancy start was calculated by subtracting 
gestational length from the birthdate of the child, using gestational length registered in the 
MBR or 280 days when this information was missing. Women with invalid personal 
identification numbers, who did not reside in Sweden at the start of follow-up or who had 
previously been diagnosed with cancer were excluded from the population. In study III 
women who had bilateral oophorectomy before start of follow-up were also excluded since 
they were not considered at risk for ovarian tumors.  
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Birth cohorts in studies II and IV 
By using information from the PDR and the Q-IVF registry, all women who had received 
ovulation induction or COS between 2005 and 2012 were identified. A cohort of women who 
were between 20 and 45 years old during this time, meaning women born 1960–1992, was 
established in order to investigate associations between ovarian stimulation treatments and 
breast cancer risk in study II. The women were followed from their 20th birthday or July 1st 
2005, whichever occurred last. Women who were alive and residing in Sweden at the start of 
follow-up were included, and women with invalid personal identification numbers, who had 
been diagnosed with cancer or had given birth to four or more children before start of follow-
up were excluded. Lexis diagrams, with attained age on the vertical axis and calendar year on 
the horizontal axis, are useful to visualize birth cohorts. The darker grey area in Figure 4.1 
represents the follow-up time for this cohort.  
 
In study IV, a cohort of women who could have been diagnosed with infertility or related 
disorders in the NPR was established. Hence, the cohort included women born 1942–1992, 
who were between 20 and 45 years old in 1987 (when the NPR reached complete national 
coverage). The women were followed from age 20 and any diagnosis related to infertility 
from age 15 was included. Both the grey areas in Figure 4.1 represent the follow-up time for 
this cohort. Women with invalid personal identification numbers, who had died, been 
diagnosed with cancer or had more than four children before age 20 were excluded.  
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Figure 4.1 Lexis diagram of the birth cohorts in study II and IV. 
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4.3.1 Bias in observational studies 
Observational studies are used to measure associations between exposure and outcome in a 
population. However, researchers are often interested in whether the exposure actually has a 
causal effect on the outcome and not just that the two factors tend to appear together. In two 
theoretical scenarios where the exposure was either present or absent while all other 
conditions were held constant, the exposure has a causal effect if the two outcomes differ. In 
epidemiological studies, only one of the scenarios can be observed for each individual, while 
the scenario that did not occur is called the counterfactual. In order to evaluate whether an 
observed association may be due to a causal effect, the counterfactual can be approximated 
by ensuring that all other factors are equally distributed between exposed and unexposed 
individuals.  
In observational studies, unequal distribution of these factors can be caused by systematic or 
random error. Random error is variation due to chance, which normally decreases with 
increasing sample size. The main sources of systematic error can be classified into three 
categories: information bias, selection bias and confounding.  
Information bias 
Information bias results from inadequate methods of measuring the exposure or outcome 
variables. Information bias is referred to as measurement error for continuous variables and 
misclassification for categorical variables. If the rate of misclassification differs depending on 
exposure or outcome category, called differential misclassification, it can result in over- or 
underestimation of the effect. Non-differential misclassification generally leads to larger 
variation in the data, which can cause an underestimation of the effect. 
Selection bias 
Selection bias occurs if the participants in the study are not representative of the population, 
in particular with regards to the exposure distribution. In cohort studies, selection bias can be 
caused by differential loss to follow-up, or if non-responders differ from those who do 
respond to questionnaires.  
Confounding 
A confounder is a factor that influences the likelihood of both the exposure and the outcome 
(Figure 4.2). Confounding can cause bias in both directions (either inflate an estimate or bias 
it towards the null). In clinical trials, confounding is avoided by randomizing individuals to 
either receive the exposure or not. In observational studies, confounding can be handled by 
stratification or by adjustment in regression analyses. A factor that lies in the causal pathway 
between the exposure and the outcome is called a mediator (Figure 4.2). Adjusting for a 
mediator blocks this pathway, resulting in a model that can only estimate the direct effect of 
the exposure on the outcome without mediation and not the total causal effect. 
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Figure 4.2 Directed Acyclic Graphs demonstrating a confounder (left) and a mediator (right). 
 
4.4 STATISTICAL METHODS 
There are many different statistical approaches used in epidemiological research. In general, 
the methods are used to compare the outcome (e.g. cancer incidence) among exposed and 
unexposed individuals and to assess the variability in the data to give a measure of how likely 
it is that the result is due to chance. In this thesis work, two different types of regression 
models were used to estimate associations with 95% confidence intervals (CI) while adjusting 
for confounding factors. 
4.4.1 Linear regression 
Linear regression is normally used for continuous outcomes, such as the mammographic 
density measures in study I. A simple linear regression model tries to fit observed data of an 
outcome variable 𝜇 and a single explanatory variable 𝑥 to a linear equation, as shown in 
Equation 4.1. 
 𝜇 = 𝛽0 + 𝛽1𝑥 Equation 4.1 
The coefficient 𝛽0 is known as the intercept and can be interpreted as the mean value of the 
outcome for an unexposed individual, i.e. where 𝑥 = 0. The regression coefficient 𝛽1 is the 
mean difference of the outcome 𝜇 for a one-unit change of the exposure variable 𝑥. The linear 
regression model can easily be expanded to fit data with more than one explanatory variable 
𝑥, usually a number of potential confounders 𝑥2 to 𝑥𝑛. This model, called multiple linear 
regression, is described in Equation 4.2. 
 𝜇 = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ +  𝛽𝑛𝑥𝑛 Equation 4.2 
Linear regression is based on several underlying assumptions about the data. There are a 
number of extensions of linear regression that allow some of these assumptions to be relaxed. 
In study I, the associations between infertility, fertility treatment and mammographic density 
were analyzed using a generalized linear model (GLM) with a log link to account for the 
skewed outcome distribution (Equation 4.3).  
 log(𝜇) = 𝛽0 + 𝛽1𝑥1 + ⋯ +  𝛽𝑛𝑥𝑛 Equation 4.3 
The GLM yielded an intercept (𝛽0) equal to the log mean density in the reference group and 
beta coefficients (𝛽𝑖) equal to the log mean ratios between exposed and unexposed groups. 
Confounder 
Exposure Outcome 
Mediator 
Exposure Outcome 
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Consequently, mean ratios are obtained by exponentiating 𝛽𝑖. In study I, the log mean ratios 
for the main exposures 𝑥𝑖 were transformed to mean differences by subtracting the mean ratio 
of the unexposed group from that of the exposed group, as explained in Equation 4.4.  
Mean difference = exp(𝛽0 + 𝛽𝑖) − exp(𝛽0) = exp(𝛽0) ∗ (exp(𝛽𝑖) − 1) Equation 4.4 
The mean difference is interpreted as the difference in mean mammographic density between 
the exposed and unexposed group on the absolute scale, while the mean ratio is a relative 
measure interpreted as the ratio of the mean density in the exposed over unexposed group. A 
mean difference of 0, or a mean ratio of 1, implies that the exposure is not associated with the 
outcome.  
4.4.2 Survival analysis 
In cohort studies, the individuals are usually followed for different amounts of time during 
which they are at risk for the outcome. Regression models that account for different lengths 
of follow-up time include Cox regression and Poisson regression models. If the outcome does 
not occur before the end of the study, for example if the individual is lost to follow-up for 
other reasons, the follow-up time is said to be censored. In studies of cancer incidence, the 
outcome of interest is a diagnosis of cancer while censoring can be due to other events such 
as emigration or death.  
In studies II-IV, cancer incidence was examined using the Cox proportional hazards model. 
The hazard function 𝜆(𝑡) describes the instantaneous event rate at time 𝑡, for those who are 
alive at time 𝑡. In the Cox model, 𝜆(𝑡) is modelled as a function of covariates 𝑥𝑖 (Equation 
4.5), where 𝜆0(𝑡) denotes the baseline hazard function, 𝑥1- 𝑥𝑛 are covariates and 𝛽1- 𝛽𝑛 their 
estimated coefficients. 
 𝜆(𝑡) =  𝜆0(𝑡) ∗ exp(𝛽1𝑥1 + ⋯ +  𝛽𝑛𝑥𝑛) Equation 4.5 
The hazard ratio (HR) of covariate 𝑥𝑖 is given by the exponent of its coefficient (exp(𝛽𝑖)). 
For the exposure variable, the HR is the ratio of the hazard in the exposed over the unexposed 
group, for a certain period of time. When studying cancer incidence, the hazard represents the 
incidence rate while the HR is an incidence rate ratio. The Cox model estimates these 
coefficients without making any assumptions about the shape of the baseline hazard.  
A strong assumption in the Cox model is that the hazards are proportional over time, meaning 
that the effects of the covariates on the hazard function are assumed to be multiplicative for 
the duration of follow-up. The proportional hazards assumption can be formally tested using 
Schoenfeld residuals to tests the null hypothesis of proportionality. By plotting the hazard 
functions (e.g. incidence rates) of each exposure category, the proportionality can also be 
assessed visually.  
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Since age is a strong risk factor for cancer, attained age was used as the underlying time-scale 
in all models and the baseline hazard was the incidence rate over age. Hence, all the 
estimated HRs from the Cox model were adjusted for age. When there is more than one time-
line of interest, the follow-up time of each individual can be split into several intervals to 
control for effects of these timescales. In studies II-IV, the follow-up time was split by 
calendar period. 
Variables that are not constant during follow-up can be entered into the model as time-
varying covariates. In studies II and III, fertility treatments were treated as time-varying 
exposures, as were diagnoses related to infertility in study IV. Parity was included as a time-
varying covariate in studies II-IV. In studies III and IV, bilateral oophorectomy, 
salpingectomy and hysterectomy were also included as time-varying covariates when not 
used for censoring.   
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5 RESULTS 
The main findings from each study are summarized below. A simplified directed acyclic 
graph summarizing the study aims is presented in Figure 5.1. 
I. Overall, infertile women had a higher absolute dense volume compared to women 
without fertility problems. Among infertile women, COS was associated with a higher 
absolute dense volume while other hormonal treatments were not. Percent volumetric 
density was not associated with infertility or fertility treatments. 
II. Women who gave birth following ART did not have a higher incidence of breast 
cancer compared to women with non-ART births. Neither COS nor ovulation 
induction treatments were associated with a higher breast cancer incidence, compared 
to women who did not receive treatment. 
III. Compared to women with non-ART births, women who gave birth following ART 
had a higher incidence of both ovarian cancer and BOT. Compared to infertile women 
who conceived without ART, women with ART births had a statistically significant 
higher incidence of ovarian cancer but not BOT. 
IV. Women diagnosed with infertility had a higher incidence of ovarian and endometrial 
cancer, but not of breast cancer. Ovarian cancer incidence was higher in women 
diagnosed with endometriosis, and in nulliparous women with ovulatory disturbances, 
compared to women with none of the diagnoses. Endometrial cancer incidence was 
higher in women with ovulatory disturbances, but not in women with endometriosis. 
 
 
 
 
  
Breast cancer 
Ovarian cancer 
Endometrial cancer 
Mammographic 
density 
Infertility 
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Figure 5.1 Overview of associations explored in the included studies. 
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5.1  STUDY I 
Study I examined the associations between infertility, hormonal infertility treatments and 
mammographic density in a cohort of 43,313 women aged 40-69 years at mammography 
screening. The main results from this study were: 
 One fifth of all women reported a history of infertility. Among these women, 66.4% 
reported no hormonal treatment, 17.6% had gone through COS for ART and another 
16.0% had ovulation induction only.  
 Among nulliparous women 31.9% had tried to become pregnant, out of which 59.6% 
had received no hormonal treatment, 28.5% had been treated with ART and another 
11.9% with ovulation induction. 
 Women with a history of infertility had 1.53 cm3 higher absolute dense volume (95% 
CI 0.70–2.35), compared to women with no infertility in the multivariable adjusted 
analysis. Since non-dense volume was also higher (adjusted mean difference 7.6, 95% 
CI 1.8–13.4), percent dense volume did not differ between infertile and non-infertile 
women (adjusted mean difference 0.09, 95% CI -0.06–0.23). 
 Compared to infertile women who did not receive hormone treatment, absolute dense 
volume was higher among infertile women treated with ART (adjusted mean 
difference 3.22, 95% CI 1.10–5.33), but not among women who had only gone 
through ovulation induction (adjusted mean difference -0.94, 95% CI -2.77–0.89). 
 Percent dense volume did not differ between infertile women who had received either 
ART (adjusted mean difference 0.19, 95% CI -0.14–0.52) or other hormonal 
stimulation (adjusted mean difference -0.20, 95% CI -0.54–0.15), compared to 
infertile women who did not receive hormone treatment.  
 The association between absolute dense volume and ART treatment seemed to be 
stronger among nulliparous women (adjusted mean difference 7.33, 95% CI: 2.29–
11.38) than parous women (adjusted mean difference 2.21, 95% CI: -0.02–4.44), 
although the likelihood ratio test for interaction did not reach statistical significance 
(p = 0.073). 
5.2 STUDY II 
Study II investigated breast cancer incidence following ovarian stimulation in two separate 
cohorts. Associations between births following ART and breast cancer incidence were 
assessed in a cohort of parous women with a first live birth 1982–2012. The relationship 
between having had any ovarian stimulation since 2005 and breast cancer incidence was 
studied in a cohort of women born 1960–1992. The main results from each cohort were: 
Parous women 
 Among the 1,340,211 parous women in the cohort, 38,047 (2.8%) had given birth 
following ART. 
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 Just over two thirds (69.7%) of women with ART births and 6.7% of women with 
non-ART births had an infertility-related diagnosis in the NPR. 
 In multivariable adjusted analysis, the incidence of breast cancer was lower among 
women with infertility-related diagnoses and no ART birth (HR 0.83, 95% CI 0.77–
0.89) and among women with ART birth (HR 0.84, 95% CI 0.74–0.95) compared to 
women with no infertility or ART. 
 Compared to women with infertility-related diagnoses but no ART birth, women who 
gave birth following ART did not have a higher incidence of breast cancer (adjusted 
HR 1.01, 95% CI 0.88–1.17). 
 Adjusting for BMI at the start of the first pregnancy did not affect the estimates in the 
subgroup of women with information on BMI. 
Women born 1960–1992 
 Of the 1,877,140 women born 1960–1992, 39,469 (2.1%) had gone through COS for 
ART and another 26,232 (1.4%) had received ovulation induction treatment between 
2005 and 2012. 
 Infertility-related diagnoses were recorded in the NPR for 75.3% of women with COS 
treatment, 53.9% of women with ovulation induction and 5.8% of women with no 
ovarian stimulation. 
 The incidence of breast cancer was not higher among women who received COS 
(adjusted HR 0.86, 95% CI 0.69–1.07) or among women who received other 
hormonal fertility treatments (adjusted HR 0.79, 95% CI 0.60–1.05), compared to 
women with no infertility-related diagnosis or ovarian stimulation. 
 Compared to women with infertility-related diagnoses and no ovarian stimulation, the 
breast cancer incidence was not higher among women treated with COS (adjusted HR 
1.03, 95% CI 0.82–1.30) or ovulation induction (adjusted HR 0.95, 95% CI 0.71–
1.28).  
 The results did not seem to differ between parous and nulliparous women, and the 
likelihood ratio test for interaction was not significant (p adjusted = 0.1847).  
5.3  STUDY III 
Study III investigated the incidence of ovarian cancer and BOT among women with and 
without a diagnosis of infertility or ART treatment, in the cohort of parous women. The main 
results were: 
 A diagnosis of infertility was recorded in the NPR for 66.3% of women with ART 
births and 3.8% of women with non-ART births. 
 Women who had given birth following ART had a higher incidence of ovarian cancer, 
both compared to women with no infertility or ART (adjusted HR 2.43, 95% CI 1.73–
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3.42) and compared to infertile women who conceived without ART (adjusted HR 
1.79, 95% CI 1.18–2.71).  
 The incidence of BOT was higher among women with ART birth when compared to 
women with no infertility or ART birth (adjusted HR 1.91, 95% CI 1.27–2.86). When 
comparing to infertile women with non-ART birth, the association was not 
statistically significant (adjusted HR 1.48, 95% CI 0.90–2.44). 
 Excluding the first year of follow-up did not substantially change the results of the 
main analyses for either ovarian cancer or BOT.  
 Neither BMI nor smoking before pregnancy appeared to influence the main results. 
5.4  STUDY IV 
Study IV investigated the relationship between infertility, with and without ovulatory 
disturbances or endometriosis, and incidence of cancer among women born 1942–1992. The 
main results were: 
 Of the 2,882,847 women in the cohort, 4.1% had a diagnosis of infertility. Among 
infertile women, 16.4% had been diagnosed with ovulatory disturbances and 11.9% 
with endometriosis. Among non-infertile women, the corresponding figures were 
1.5% and 2.0%, respectively. The overlap between these diagnoses and the number of 
incident cancer cases in each group are presented in Figure 5.2.  
 
Figure 5.2 Venn diagram of exposure overlap and number of incident cancers in study IV. 
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 The incidence of ovarian cancer was higher among women with ovulatory 
disturbances (adjusted HR 1.53, 95% CI 1.18–1.98), endometriosis (adjusted HR 
1.77, 95% CI 1.53–2.05) and infertility (adjusted HR 1.53, 95% CI 1.36–1.72), 
compared to women with none of these diagnoses. The highest incidence of ovarian 
cancer was seen in women diagnosed with both infertility and endometriosis (adjusted 
HR 2.19, 95% CI 1.70–2.82). 
 In analyses stratified by either parity or age, the association between ovulatory 
disturbances and ovarian cancer was only significant among nulliparous women and 
before age 50, respectively. The associations with endometriosis and infertility 
remained significant also among parous women as well as in older ages. 
 Women diagnosed with either infertility (adjusted HR 1.21, 95% CI 1.07–1.38) or 
ovulatory disturbances (adjusted HR 1.45, 95% CI 1.12–1.88) had a higher incidence 
of endometrial cancer, and the highest incidence was found in women with both these 
diagnoses (adjusted HR 2.90, 95% CI 2.05–4.08). 
 The incidence of endometrial cancer was not higher among women exclusively 
diagnosed with endometriosis (adjusted HR 0.94, 95% CI 0.76–1.17), or in 
combination with infertility (adjusted HR 0.87, 95% CI 0.58–1.30). 
 Being diagnosed with both infertility and ovulatory disturbances was associated with 
a higher incidence of endometrial cancer in both nulliparous (adjusted HR 3.46, 95% 
CI 2.22–5.38) and parous women (adjusted HR 2.28, 95% CI 1.32–3.93). A diagnosis 
of either ovulatory disturbances (adjusted HR 2.20, 95% CI 1.51–3.20) or infertility 
(adjusted HR 1.28, 95% CI 1.08–1.53) was associated with a higher incidence of 
endometrial cancer only among nulliparous women. 
 When stratifying by age, the higher incidence of endometrial cancer among women 
diagnosed with infertility and/or ovulatory disturbances was only present below the 
age of 50. None of the infertility-related diagnoses were associated with a 
significantly higher incidence of post-menopausal endometrial cancer. 
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6 DISCUSSION 
6.1 BREAST CANCER RISK 
Neither infertility nor ovarian stimulation seem to increase the risk of breast cancer, although 
these factors may have an influence on mammographic density. 
There was no evidence of an increased breast cancer risk among infertile women in studies II 
and IV. While these findings are in agreement with many previous studies (45,91,108–110), 
others have reported higher risks associated with infertility (38–40), endometriosis (41,42) 
and PCOS (43,44). However, none of the studies reporting a higher risk included adjustment 
for parity. Since nulliparity is a risk factor for breast cancer that is more common among 
infertile women, these studies may have overestimated cancer risk in this population. 
Similar to the findings of most previous studies (38,45–50), women who had gone through 
ovarian stimulation did not have an increased risk of breast cancer in study II. In contrast to 
these results, a Norwegian study found a higher risk of breast cancer among women with 
ART births compared to other parous women (53). Since having an ART birth was not 
associated with a higher risk compared to either infertile or non-infertile parous women in 
study II, there may have been other differences between the respective study populations in 
Sweden and Norway. 
Two recent meta-analyses have concluded that ART treatments do not seem to influence 
breast cancer risk (9,52), although one of them reported a slightly higher risk of breast cancer 
when restricting analyses to non-ART treatments of infertility performed before 1980 (9). 
However, this finding was based on only three studies and was not adjusted for parity. A 
Swedish study based on an historical cohort of infertile women reported a higher risk 
specifically among women who had gone through four or more cycles of high-dose 
clomiphene citrate stimulation (24). Analyses of breast cancer risk following ovulation 
induction in study II were based on treatments performed 2005 or later. These results may not 
be representative for women who received high doses of hormonal stimulation before 1980 
since it is likely that treatment indications, drug types and dosage have changed between the 
two time periods.  
Two previous studies have found a higher risk of breast cancer following gonadotropin use 
specifically among women who remain nulliparous after treatment (54,55). In study II, 
neither nulliparous nor parous women had an increased risk of breast cancer following 
ovarian stimulation, based on a mean follow-up of six to seven years. While it is possible that 
this follow-up was too short to identify an increase in long-term risk, studies on oral 
contraceptive and hormone replacement therapy use have only found increased risks of breast 
cancer linked to current or recent use (31). 
The results from study I indicated that infertile women had slightly more dense tissue in the 
breast. Among infertile women, ART was associated with a higher dense volume compared 
to receiving no hormonal treatment. While this could implicate a long-term effect of ART 
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treatments on the breast tissue, it may also be explained by differences in the underlying 
infertility between women who had been treated with ART and those who had not. 
Additionally, the observed differences were small and it remains unclear whether they could 
influence breast cancer risk. A recent study on mammographic density reported that the risk 
of breast cancer increased by 3% for every 10 cm3 higher absolute dense tissue, measured 
using the same method as in study I (61). Based on these results, the higher absolute dense 
volume in study I among women who had gone through ART could potentially correspond to 
a 1% increased risk of breast cancer.  
6.2 OVARIAN CANCER RISK 
Overall, infertile women had a higher risk of ovarian cancer than non-infertile women in 
studies III and IV. Ovarian cancer risk was higher among women diagnosed with infertility, 
endometriosis, and in a subpopulation of women with ovulatory disorders in study IV, 
compared to women with none of these diagnoses. In study III, women who had given birth 
following ART treatments had a higher risk of ovarian cancer and BOT.  
Most previous studies have reported standardized incidence ratios (SIRs) of ovarian cancer 
among infertile women compared to the general population (38–40,45,83,111). Among these, 
all but two (38,45) found higher risks among infertile women. In addition, a cohort study in 
the United States reported a higher risk of ovarian cancer among infertile women (73). Only 
one of these studies adjusted for parity (39), while two case-control studies found no 
increased risks among infertile women when adjusting for parity (77,78). However, the risk 
of ovarian cancer was higher among infertile women even after adjusting for parity in study 
IV, implying that other aspects of infertility contributed to the increased risk in this 
population. 
Women diagnosed with endometriosis had a higher risk of ovarian cancer in study IV. This is 
consistent with the findings of a meta-analysis from 2014 (112) as well as several recent 
studies (41,68,91,113). The mechanism behind this association is not entirely understood, 
though it is likely related to oxidative stress caused by retrograde menstruation as well as 
changes in the microenvironment that promotes carcinogenesis (114). The risk of ovarian 
cancer was also higher among nulliparous women diagnosed with ovulatory disturbances. So 
far, most previous studies have not found any increased risk in women with PCOS 
(44,110,115,116), although one study reported a higher risk of ovarian cancer among women 
with irregular menstruation (72). 
In study III, the risk for ovarian cancer was increased in women with ART-births. Most 
previous studies have not found a higher risk of ovarian cancer following ART (46–
48,50,68,75,76), including the few that compared the risk to that of infertile women 
(47,68,76). The results from study III also indicated that part of the association was due to the 
underlying infertility since the effect was smaller compared to other infertile women.  
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The higher risk following ART should also be considered in relation to the low incidence of 
ovarian cancer in the general population. In Sweden, five out of 1,000 women are expected to 
be diagnosed with ovarian cancer before 65 years of age (117). Based on this number, the 
higher incidence rates in study III would correspond to an absolute risk of seven in 1,000 
among infertile women and eleven in 1,000 among women who have gone through ART 
treatment, before age 65. Accordingly, the identified difference in risk between infertile 
women conceiving with and without the help of ART is only four in a thousand. 
The risk of BOT was also higher following ART births when compared to parous women 
with no infertility, similar to the results of a recent study from Norway (50). When comparing 
to infertile women with non-ART births the risk was not significantly higher after ART, 
indicating that the higher risk was confounded by the underlying cause of infertility. 
However, the point estimate was close to 1.5 suggesting that the study might have been 
underpowered to identify a modest increase in risk. Two previous studies have reported 
higher risks of BOT following ART treatments after adjusting for parity (76,87).  
6.3 ENDOMETRIAL CANCER RISK 
The results from study IV showed that endometrial cancer risk was higher among women 
diagnosed with infertility or ovulatory disturbances, but not in women with endometriosis, 
compared to women with none of these diagnoses.  
The risk of endometrial cancer was higher in infertile women overall, with a stronger 
association among nulliparous women. These results are in line with those of a pooled case-
control study that found infertility and nulliparity to be independently associated with 
endometrial cancer risk (89). Some previous studies have reported higher SIRs of 
endometrial cancer in infertile women when adjusting for age and calendar period (38,40,45), 
while one study found no increased risk after adjusting for parity (118).  
Endometrial cancer risk was higher in women diagnosed either with infertility or ovulatory 
disturbances, and women with both of these diagnoses appeared to have the highest risk. This 
increased risk is most likely due to PCOS, which has consistently been found to be associated 
with endometrial cancer (44,110,116,119). Since PCOS is a common cause of infertility, this 
disorder likely contributed to the higher risk of endometrial cancer seen among women 
diagnosed with infertility alone. 
There was no evidence of an increased risk of endometrial cancer among women with 
endometriosis. These findings are consistent with several previous studies (42,91,92,120). A 
few studies have reported that women with endometriosis have a higher risk of endometrial 
cancer (41,90,121,122). The studies have different methodological approaches and designs 
that could explain the contradictory results. 
It was not possible to separate the potential effects of fertility treatments from that of 
infertility and related diagnoses in study IV. It is reasonable to assume that many women 
diagnosed with infertility also received some fertility treatment. A recent systematic review 
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reported that high doses of clomiphene citrate stimulation were associated with a higher 
endometrial cancer risk when comparing to other infertile women (93). Nevertheless, the 
authors noted that the association was likely confounded by the underlying cause of infertility 
since clomiphene citrate is commonly used to treat infertility due to PCOS. Further, a meta-
analysis of six studies found no increased risk of endometrial cancer following fertility 
treatments (123).  
6.4 METHODOLOGICAL CONSIDERATIONS 
A key strength of the studies in this thesis is the use of national health and population 
registers with essentially complete coverage, enabling the identification of large study cohorts 
with reliable information on fertility treatments, cancer incidence and many important 
confounding factors. Another key strength is the utilization of survival analysis that 
accurately accounts for differences in age between exposure groups as well as loss to follow-
up, while also allowing for correct adjustments of changes over calendar period. 
6.4.1 Choice of comparison group 
Many previous studies have compared the risk of cancer in infertile women to the expected 
number of cases in the general population by calculating SIRs. The expected number of cases 
is usually calculated on the basis of age and calendar period. Therefore the resulting estimates 
will not be adjusted for other risk factors, most importantly parity. Since several risk factors 
for cancer are more common among infertile women, comparisons to the general population 
may overestimate the effect of treatment itself.  
In all of the included studies, the first comparison group was women without known fertility 
problems from the same cohort. While these models can be adjusted for parity and other 
confounders, the comparison cannot be used to separate potential effects of fertility 
treatments from those of infertility. In order to distinguish between these factors, a separate 
comparison group of infertile women with no known ovarian stimulation was identified in 
studies I-III. This comparison can give a better estimate of a potential treatment effect, 
assuming that causes of infertility are similarly distributed among women with and without 
treatment. However, the causes and severity of infertility may differ between the groups 
potentially causing residual confounding. 
6.4.2 Information bias 
Study I was mainly based on data from questionnaires that were filled out at the time of 
mammographic screening. This study design may cause recall bias, if the accuracy of the 
exposure information differs depending on the outcome. Since women were not aware of 
their mammographic density measures, it seems unlikely that it had any influence on the 
questionnaire answers. Most women will probably remember if they have ever gone through 
infertility and fertility treatments. However, older women may be less likely to recall the 
specific drug used in ovarian stimulations that were performed a long time ago, potentially 
causing some misclassification of treatment types. 
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In studies II-IV, information from the NPR was used to identify women with infertility and 
related diagnoses. As the NPR only covers in-patient care prior to 2001 some infertile women 
were likely misclassified as non-infertile, which could bias the estimates towards the null for 
infertility. Given the large population of non-infertile women in the comparison group, any 
such effect is likely to be small. However, some causes of infertility, such as ovulatory 
disturbances, are more likely to be diagnosed in out-patient care and may therefore have been 
more common among women with ART births than in the infertile comparison group.  
In studies II and III, women who had ART treatments outside of Sweden or conceived 
spontaneously following an unsuccessful ART cycle were likely classified as having non-
ART births. These misclassifications could bias the estimates towards the null, although 
likely to a small extent.  
In study II, information on any dispensations of ovarian stimulation drugs was obtained from 
the PDR. Since the PDR was only available from July 2005, women treated before then and 
not after were classified as untreated. In addition, no information on whether the women 
actually took the medication was available and some untreated women may have been 
categorized as treated. Any such misclassification could bias the estimates towards the null.  
Information bias can also be caused by differential misclassification of the outcome. 
Increased surveillance following ART could potentially influence incidence rates due to 
earlier detection. However, the mean age at diagnosis of BOT and ovarian cancer was not 
lower in exposed than unexposed women in study III. Further, since there is no screening 
program for ovarian cancer in Sweden, this is unlikely to explain the higher risk after ART. 
6.4.3 Selection bias 
Selection bias occurs when the distributions of exposure among cases and/or controls are 
different from that of the population.  
In study I, non-responders could be a potential cause of selection bias. However, as the 
Karma cohort was established for the broader purpose of risk prediction of breast cancer and 
the questionnaire measures a wide range of different factors, it is unlikely that previous 
infertility or fertility treatments would influence women’s decision to participate.  
In studies based on population registers, selection bias can be caused by differential loss to 
follow-up. Although between 4 and 6% of the women in studies II-IV emigrated from 
Sweden during the respective study periods, it seems unlikely that emigration would be 
related to whether or not a woman will experience infertility or require fertility treatments. 
6.4.4 Confounding and mediation 
Factors that are associated with cancer and infertility or fertility treatment could bias the 
results of the included studies if they are not adjusted for. Each covariate included in the 
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analyses was chosen a priori based on the current knowledge of their potential influence on 
both the exposure and outcome.  
Through linking of the national population-based registers, several important potential 
confounders were identified and included in the studies, including age, parity, education, 
calendar period and country of birth.  
Age is the most important risk factor for the cancers in this thesis. In study I, age was 
included as a categorical variable to allow for non-linear associations across different age 
groups. In studies II-IV attained age was used as time-scale, which is the most efficient way 
to adjust for this confounder in a Cox model (124).  
Calendar period was included to indirectly adjust for unmeasured factors that have changed 
over time, such as ovarian stimulation treatment protocols and cancer screening programs. 
Similarly, education level and country of birth are not confounders per se but markers of 
other factors that may influence the results such as social inequality and health seeking 
behavior. 
Parity was included in all multivariable adjusted models as it is strongly linked to infertility, 
mammographic density and cancer risk. Since parity could also be an effect modifier, 
analyses that included nulliparous women were stratified by parity.  
The questionnaire in study I included information on age at menarche, menopausal status, 
BMI, cigarette smoking and alcohol consumption at the time of mammography. Adjusting for 
BMI attenuated the association between infertility and absolute dense volume, while the other 
factors had very modest effects, if any.  
BMI and smoking during pregnancy was recorded in the MBR for a subset of parous women 
in studies II and III. Models adjusted for BMI were included as sensitivity analyses in both 
studies, while models adjusted for smoking during pregnancy were added as sensitivity 
analyses in study III. Neither of these factors appeared to influence the associations between 
infertility, fertility treatments and cancer risk. However, high BMI could act as a mediator 
between ovulatory disturbances and endometrial cancer risk since PCOS may cause weight 
gain (19).  
Age at first birth was not included in study I. The associations in parous women may have 
been mediated by age at first birth, as infertility problems are likely to delay childbearing and 
women who give birth later generally have higher mammographic density (62). When 
designing studies II-IV, age at first birth was included in order to assess associations that 
were not mediated by this factor.  
In studies II-IV unmeasured factors that could cause residual confounding include ovulation 
induction treatments, age at menarche and menopause, oral contraceptive use and cause of 
infertility.  
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Since ovulation induction is the first-line treatment for anovulatory infertility, some of the 
women in study II and III had likely received clomiphene citrate and/or low-dose 
gonadotropin stimulation. This could potentially overestimate the effect of ART when 
comparing to non-infertile women. Assuming that ovulation induction was more common 
among infertile women with non-ART births, it could bias the results towards the null when 
comparing women with ART births to this group. However, most previous studies have not 
found any link between ovulation induction and the risk of breast or ovarian cancer (8). 
Early age at menarche is a risk factor for breast and ovarian cancer, and a few studies have 
suggested that late menarche is associated with a slightly higher risk of infertility (125,126). 
Confounding by age at menarche could therefore have underestimated the associations in 
study IV. 
Menopause occurs after the reproductive period and is not technically a confounder. Some 
studies have suggested that pre- and postmenopausal breast cancer may have different risk 
factors (127,128). To investigate whether the studied associations differed by menopausal 
status, age 50 was used as a proxy for menopause in studies II and IV.  
Oral contraceptives could potentially have confounded the results of study III if infertile 
women used them less, as they are known to lower the risk of ovarian cancer. However, oral 
contraceptive use is unlikely to differ between groups before attempting to get pregnant, and 
they are also prescribed as treatment for PCOS and endometriosis.  
6.4.5 Random error 
In general, utilizing large cohorts should minimize the risk that the results of the included 
studies were influenced by random error. However, the small number of exposed cases led to 
imprecise estimates in analyses of BOT risk following ART treatments, as well as ovarian 
cancer risk among women diagnosed with ovulatory disturbances and infertility. Random 
error can result in either an over- or underestimation of the true effect.  
6.4.6 Other limitations 
For most of the study period (1982–2004), there was no information on ART treatments that 
did not lead to live births nor the stimulation protocol used. Therefore, it was not possible to 
study cancer risk in relation to number of ART cycles or total gonadotropin dose. The 
presence or absence of a dose-response relationship could have provided useful clues in 
determining whether the associations between ART treatments and ovarian tumor risks were 
due to the treatment or the underlying infertility.  
6.5 GENERALIZABILITY 
While ART treatments have been performed in Sweden for more than 30 years, few women 
received the treatment during the first decade, so the majority of women who have gone 
through ART are still young. In study II and III, there were no diagnoses of cancer above the 
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age of 60 among women with ART births. Therefore, the results from these studies may not 
be generalizable to women of older ages.  
Although the total follow-up time was longer in study IV, infertility and related diagnoses 
were more common in recent years due to the improved coverage of the NPR. Since follow-
up time was shorter in some exposure groups, especially for women diagnosed with ovulatory 
disturbances, the results for post-menopausal cancer risks were imprecise. The lack of 
significant results in women over 50 should not be interpreted as evidence that there is no 
association in this age group as it could also be due to a lack of power. 
Only information on ART treatments that resulted in live births was available between 1982 
and 2005. On average, 60-70% of couples who receive ART treatments succeed in having a 
child (129) and many women who go through these treatments will remain childless. Since 
having children lowers the risk of both breast and ovarian cancer, it is possible that an 
increased risk from treatment may be masked by the protective effect of parity. In study II, it 
was possible to investigate breast cancer risk following any ovarian stimulation by using 
information from the PDR, with a follow-up of eight years. This analysis could not be 
repeated for ovarian cancer or BOT due to the small number of exposed cases and the results 
from study III might not be representative for women who remain nulliparous after treatment. 
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7 CONCLUSIONS AND IMPLICATIONS 
Neither infertility nor ovarian stimulations seem to increase the risk of breast cancer. Breast 
cancer risk was not higher among women diagnosed with infertility, endometriosis or 
ovulatory disturbances than in women with none of these diagnoses. Further, women treated 
with ART did not have a higher breast cancer risk compared to women who had not gone 
through treatment. These findings are especially reassuring since breast cancer is the most 
common cancer type in women. 
Overall, infertile women have a higher risk of ovarian cancer than women with no infertility-
related diagnoses. Endometriosis was consistently associated with a higher risk of ovarian 
cancer, both in parous and nulliparous women. In addition, ovulatory disorders may be 
associated with a higher risk of ovarian cancer specifically among nulliparous women, 
although the reasons for this association are unclear. 
Women who have gone through ART have a higher risk of ovarian cancer and borderline 
ovarian tumors. Although the risk following ART was compared to that of other infertile 
women, it is still possible that this association was confounded by the underlying causes of 
infertility. Ovarian cancer is a rare disease and the absolute increases in risk were small. 
Since the risk of being diagnosed with ovarian cancer is still very low among women who 
have received ART, the findings should not be a cause for concern for individual infertile 
women or treating physicians. Nevertheless, the results highlight the importance to continue 
investigating cancer incidence in this population.  
Endometrial cancer risk is higher in women with ovulatory disorders, especially in 
combination with infertility. This is likely due to PCOS, since this disorder is known to 
increase endometrial cancer risk through high levels of estrogen without counteraction by 
progesterone. Women with endometriosis did not have a higher risk of endometrial cancer.  
In summary, breast cancer risk is not likely to be influenced by infertility or fertility 
treatments, while ovarian and endometrial cancer are more common in some groups of 
infertile women. Further, ART treatments may be associated with a small increase in the risk 
of ovarian cancer and borderline ovarian tumors.  
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8 FUTURE PERSPECTIVE 
Despite their shortcomings, observational studies will continue to play an important role in 
this field of research. It is difficult, if not impossible, to perform clinical trials investigating 
long-term cancer risk.  
ART treatments are performed during a woman’s reproductive years while cancer is more 
likely to be diagnosed in older women. Even longer follow-up time will be required to fully 
investigate the possible long-term risks of ART.  
Although the studies in this thesis are some of the largest to date, some analyses were still 
limited by low power. One way to overcome this problem is to perform analyses on pooled 
data. Nordic collaborations are promising since these countries have similar health care 
systems as well as population and health registers. 
Many new opportunities in this research field are opening up thanks to clinical registers with 
improved coverage and more detailed information. With the introduction of specialized ART 
registries in Sweden and many other countries, it is now possible to include unsuccessful 
cycles as well as drug type and dosage. Future studies will therefore be able to investigate 
potential dose-response relationships between different stimulation protocols and cancer risk 
in both parous and nulliparous women.  
In order to further disentangle potential effects of treatment, future studies should also include 
comparison groups of infertile women. In Sweden, the introduction of ICD-10 and the 
inclusion of specialist out-patient care in the NPR has resulted in better coverage and more 
detailed information on infertility than previously. Using this information, future studies may 
be able to adjust for specific types of infertility or to stratify analyses by infertility cause in 
order to identify whether fertility treatments may influence cancer risk. However, infertility is 
generally not investigated further than what is needed to decide on a treatment plan and 
infertility is commonly diagnosed as unexplained also in recent years. 
Since different cancer types may have different risk factors, it would be interesting to 
investigate risks separately for cancers of different morphology. Using information from the 
national quality registries for specific cancer types can provide further details about the 
cancer diagnoses. Cancer stage at diagnosis among exposed and unexposed women could 
also be compared in order to more thoroughly investigate potential surveillance bias 
following fertility treatments. 
Studies on prospective cohorts, such as the Karma study and the Uppsala-Stockholm Assisted 
Reproductive Techniques (UppStART) study (130) in Sweden, may give more insight into 
the influence of specific confounders not included in the national registers, since they can 
include more in-depth information on factors such as life style.   
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